Table 5.
Pattern of recurrence and oncologic outcomes of the relapsed patients
| Arm | Age | Histology, grade, stage | RFI (M) | Relapse sites | Relapse pattern | Salvage treatment | Outcomes |
|---|---|---|---|---|---|---|---|
| RS.1 | 34 | Endometrioid, G3, IC1 | 8.1 | Vaginal stump, liver, bladder, diaphragm, ileum, ascending colon | Disseminated | RCRS + chemotherapy | DOD |
| RS.2 | 36 | CCC, IA | 10.3 | Liver, pelvic mass | Disseminated | Chemotherapy | DOD |
| RS.3 | 37 | Endometrioid, G1, IC1 | 14.6 | Vaginal stump, rectal mass | Localized | Chemotherapy | DOD |
| RS.4 | 40 | Mucinous,G1,IC1 | 51.7 | Lung | Disseminated | Chemotherapy | AWD |
| RS.5 | 36 | Endometrioid, G1, IC1 | 55.3 | Vaginal stump, ileum, para-urethra | Localized | RCRS + chemotherapy + radiotherapy | AWD |
| RS.6 | 34 | CCC, IC1 | 4.9 | Systematic lymph nodes | Disseminated | Chemotherapy + radiotherapy | DOD |
| RS.7 | 40 | CCC, IC3 | 57.3 | Abdominopelvic cavity | Disseminated | Chemotherapy | DOD |
| RS.8 | 31 | HGSC, IC1 | 4.2 | Abdominopelvic cavity | Disseminated | Chemotherapy | DOD |
| RS.9 | 36 | CCC, IC1 | 6.4 | Abdominopelvic cavity | Disseminated | Palliative | DOD |
| FSS.1 | 24 | Endometrioid, G3, IC3 | 57.1 | Contralateral ovary | Localized | RCRS + chemotherapy | NED |
| FSS.2 | 34 | Endometrioid, G1, IC1 | 67.4 | Contralateral ovary | Localized | RCRS + chemotherapy | NED |
| FSS.3 | 29 | Mucinous, G1, IC2 | 9.2 | Contralateral ovary | Localized | RCRS + chemotherapy | AWD |
| FSS.4 | 22 | Mucinous, G1, IC1 | 36.9 | Lung | Disseminated | Chemotherapy + radiotherapy | DOD |
| FSS.5 | 25 | Mucinous, G1, IC3 | 16.3 | Contralateral ovary | Localized | RCRS + chemotherapy | NED |
RS radical surgery, FSS fertility-sparing surgery, CCC clear-cell carcinoma, RFI relapse-free intervals, DOD dead of the recorded disease, NED no evidence of disease, AWD alive with the recorded disease, RCRS re-cytoreductive surgery, HGSC high-grade serous carcinoma, TSS tumor-specific survival